Skip to main content
. 2023 Mar 27;2023(3):CD009885. doi: 10.1002/14651858.CD009885.pub3

7.1. Analysis.

7.1

Comparison 7: Non‐serious adverse events: parallel‐group trials and first‐period cross‐over trials, Outcome 1: Proportion of participants with non‐serious adverse events